WRBY
Warby Parker Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
27.44
▼ 0.02 (0.07%)
MARKET · —
Price
Open
27.54
Prev close
27.46
Day high
28.09
Day low
27.08
Volume
1.39M
Market cap
$3.39B
P/E (TTM)
457.33
52W range
14.96 – 31.00
Trailing performance
Returnvs SPY
1W
+5.91%
+7.3%
1M
+12.88%
+9.1%
3M
+12.00%
+8.9%
6M
+15.73%
+4.7%
YTD
+25.93%
+13.6%
1Y
+3.31%
-16.7%
3Y
+121.65%
+47.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$3.39B
Enterprise value$3.35B
Revenue (TTM)$911.61M
Gross profit$484.23M
EBITDA$41.47M
Net income$7.74M
EPS (TTM)$0.06
Free cash flow$9.53M
Total cash$292.67M
Total debt$250.98M
Book value / share$3.06
Shares outstanding108.24M
Float94.62M
Short % of float20.01%
Dividend yield—
Beta (5Y)1.93
Valuation & profitability ratios
Trailing P/E457.33
Forward P/E44.96
PEG ratio—
Price / sales—
Price / book8.96
EV / revenue3.68
EV / EBITDA80.79
Gross margin53.12%
Operating margin-3.60%
Profit margin0.85%
Return on equity2.06%
Return on assets-1.02%
Debt / equity64.03
Current ratio2.27
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $871.90M | $771.32M | $669.76M | $598.11M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $1.64M | -$20.39M | -$63.20M | -$110.39M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $1.64M | -$20.39M | -$63.20M | -$110.39M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.11 | 0.15 | +30.0% |
| Mar 2026 | 0.11 | 0.11 | +3.8% |
| Dec 2025 | 0.05 | 0.02 | -58.3% |
| Sep 2025 | 0.09 | 0.12 | +38.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.09 | 9 | $245.18M | +10.6% |
| Next quarter | 0.10 | 9 | $247.78M | +16.9% |
| Current year | 0.42 | 9 | $970.90M | +11.4% |
| Next year | 0.61 | 9 | $1.13B | +16.9% |
Analyst targets & ownership
Mean target$30.46
High target$35.00
Low target$24.00
Implied upside11.01%
Analyst count13
ConsensusBUY
Strong buy / Buy2 / 8
Hold4
Sell / Strong sell0 / 0
Held by insiders5.71%
Held by institutions116.73%
Institutions holding409
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+201.39K
Net buying
Buy transactions
20
1.03M shares
Sell transactions
13
826.07K shares
Net transactions
+33
Buys less sells
Sell : buy shares
0.8 : 1
Mixed
Insider-held shares
7.05M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 6, 26 | BLUMENTHAL NEIL HARRIS Chief Executive Officer |
— | 9.20K | — | Direct |
| Jul 6, 26 | GILBOA DAVID ABRAHAM Chief Executive Officer |
— | 54.35K | — | Direct |
| Jul 6, 26 | BLUMENTHAL NEIL HARRIS Chief Executive Officer |
SELL | 9.20K | $275.91K | Direct |
| Jul 6, 26 | GILBOA DAVID ABRAHAM Chief Executive Officer |
SELL | 54.35K | $1.62M | Direct |
| Jul 1, 26 | BLUMENTHAL NEIL HARRIS Chief Executive Officer |
— | 189.32K | — | Direct |
| Jul 1, 26 | GILBOA DAVID ABRAHAM Chief Executive Officer |
— | 213.75K | — | Direct |
| Jul 1, 26 | BLUMENTHAL NEIL HARRIS Chief Executive Officer |
SELL | 217.67K | $6.45M | Direct |
| Jul 1, 26 | RAIDER JEFFREY JACOB Director |
SELL | 22.50K | $668.70K | Direct |
| Jul 1, 26 | GILBOA DAVID ABRAHAM Chief Executive Officer |
SELL | 242.22K | $7.19M | Direct |
| Jun 29, 26 | BLUMENTHAL NEIL HARRIS Chief Executive Officer |
— | 36.30K | — | Direct |
| Jun 29, 26 | BLUMENTHAL NEIL HARRIS Chief Executive Officer |
SELL | 36.30K | $1.09M | Direct |
| Jun 18, 26 | BLUMENTHAL NEIL HARRIS Chief Executive Officer |
CONVERSION | 200.00K | $5.19M | Direct |
| Jun 16, 26 | BRIGGS TERESA Director |
SELL | 5.00K | $129.68K | Direct |
| Jun 12, 26 | MOON YOUNGME E Director |
SELL | 10.00K | $265.30K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLUMENTHAL NEIL HARRIS |
Chief Executive Officer | 431.11K | Conversion of Exercise of derivative security |
BRIGGS TERESA |
Director | 64.85K | Sale |
CUTLER JOEL E |
Director | — | Stock Gift |
GILBOA DAVID ABRAHAM |
Chief Executive Officer | 31.11K | Conversion of Exercise of derivative security |
HUNT ANDREW |
Director | 1.94M | Stock Award(Grant) |
MILLER STEVEN CLIVE |
Chief Financial Officer | 233.12K | Conversion of Exercise of derivative security |
MOON YOUNGME E |
Director | 26.06K | Sale |
RAIDER JEFFREY JACOB |
Director | 2.61M | Sale |
SINGER BRADLEY E |
Director | 125.03K | Stock Award(Grant) |
WILLIAMS RONALD A |
Director | 122.80K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
26.32
+4.27% from price
SMA 20
26.68
+2.84% from price
SMA 50
26.92
+1.95% from price
SMA 100
25.51
+7.56% from price
SMA 200
24.47
+12.12% from price
EMA 12
26.76
+2.56% from price
EMA 26
26.67
+2.90% from price
EMA 50
26.48
+3.63% from price
RSI (14)
54.0
Neutral
MACD (12,26,9)
0.09
Hist 0.14
ATR (14)
1.85
6.75% of price
Realised vol 30D
60.9%
Annualised
Bollinger upper
29.41
20, 2σ
Bollinger lower
23.96
20, 2σ
50 / 200 cross
Golden
26.92 vs 24.47
Trend bias
Above 200
+12.12%
Risk profile
Beta vs SPY
2.13
More volatile than market
Correlation to SPY
0.37
Loosely linked
Realised vol 30D
60.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-42.3%
Peak to trough
Max drawdown 5Y
-83.7%
Peak to trough
ATR 14
1.85
6.75% of price
Beta (reported)
1.93
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
1.28
Positioning, not flow
Max pain
26.00
-5.2% from spot
ATM implied vol
69.1%
Nearest strike to spot
Skew (10% OTM)
-7.6%
Calls bid over puts
Call volume
530
Contracts, this expiry
Put volume
90
Contracts, this expiry
Heaviest call OI
30.00
62 contracts
Heaviest put OI
25.50
51 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Kohl's, Ollie's, and Warby Parker Shares Plummet, What You Need To Know
StockStory · 2d ago
Warby Parker (WRBY): Buy, Sell, or Hold Post Q2 Earnings?
StockStory · 3d ago
3 Small-Cap Stocks We Steer Clear Of
StockStory · 4d ago
The Top 5 Analyst Questions From Warby Parker’s Q2 Earnings Call
StockStory · 7d ago
Warby Parker (WRBY) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
National Vision Raises Outlook as Higher-Value Customers Fuel Breakout Quarter
Exec Edge · 10d ago
WRBY Q2 Deep Dive: Intelligent Eyewear Launch and Traffic Softness Shape Outlook
StockStory · 12d ago
Warby Parker Q2 Earnings Call Highlights
MarketBeat · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.